Friday, September 29, 2023
BestWooCommerceThemeBuilttoBoostSales-728x90

Early promising results with the novel KRASG12C inhibitor divarasib – Nature Reviews Clinical Oncology


Over the past few years, several studies have demonstrated the efficacy of sotorasib and adagrasib in patients with KRASG12C-mutant solid tumours, leading to the FDA approval of both inhibitors for patients with advanced-stage non-small-cell lung cancer (NSCLC) harbouring this alteration and who have received at least one prior line of therapy. However, single-agent treatment with these agents provides limited clinical benefit. Now, data from a phase I trial show that the novel KRASG12C inhibitor divarasib is tolerable and has promising activity in patients with KRASG12C-mutant solid tumours.



Source link

Related Articles

Leave a Reply

Stay Connected

9FansLike
4FollowersFollow
0SubscribersSubscribe
- Advertisement -spot_img

Latest Articles

%d bloggers like this: